Drugs / Autologous CD19/CD20 dual-target CAR-T module
Autologous CD19/CD20 dual-target CAR-T module
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07523555 | Mar 2026 → Mar 2027 expected | B-cell acute lymphoblastic leukemia, CD4+/CD56+ hematodermic neoplasm, T-lymphoblastic lymphoma, acute myeloid leukemia +2 | Beijing Biotech | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous CD19/CD20 dual-target CAR-T module | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07523555 ↗ |
| Modality | Cell therapy | “dual-target CAR-T cell modules” NCT07523555 ↗ |
| Route | Other | “infusion of the selected dual-target CAR-T module on Day 0” NCT07523555 ↗ |